iRhythm Technologies Stock Climbs on Raised FY Guidance

Dow Jones

Oct 31, 2025

By Kelly Cloonan

Shares of iRhythm Technologies climbed after the company raised its full-year guidance as it sees growing demand for its cardiac monitoring services.

The stock rose 14% to $210 on Thursday in after-hours trading. Shares have more than doubled this year through market close.

The digital health care company now forecasts revenue of $735 million to $740 million for the year, up from its prior view of $720 million to $730 million.

The updated guidance comes after the company narrowed its loss to $5.2 million, or 16 cents a share, from $46.2 million, or $1.48 a share, a year earlier.

On an adjusted basis, loss per share was 6 cents. Analysts polled by FactSet expected an adjusted loss of 28 cents.

Revenue rose 31% to $192.9 million. Analysts expected $184.8 million.

The growth was driven in part by higher demand for cardiac monitoring services within core existing accounts, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 30, 2025 18:48 ET (22:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579019441"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579019441\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579019441?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579019441","market":"sg","top_or_hot":-1,"title":"iRhythm Technologies Stock Climbs on Raised FY Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of iRhythm Technologies climbed after the company raised its full-year guidance as it sees growing demand for its cardiac monitoring services. \n</p>\n<p>\n  The stock rose 14% to $210 on Thursday in after-hours trading. Shares have more than doubled this year through market close. \n</p>\n<p>\n  The digital health care company now forecasts revenue of $735 million to $740 million for the year, up from its prior view of $720 million to $730 million. \n</p>\n<p>\n  The updated guidance comes after the company narrowed its loss to $5.2 million, or 16 cents a share, from $46.2 million, or $1.48 a share, a year earlier. \n</p>\n<p>\n  On an adjusted basis, loss per share was 6 cents. Analysts polled by FactSet expected an adjusted loss of 28 cents. \n</p>\n<p>\n  Revenue rose 31% to $192.9 million. Analysts expected $184.8 million. \n</p>\n<p>\n  The growth was driven in part by higher demand for cardiac monitoring services within core existing accounts, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 18:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iRhythm Technologies Stock Climbs on Raised FY Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niRhythm Technologies Stock Climbs on Raised FY Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-31 06:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of iRhythm Technologies climbed after the company raised its full-year guidance as it sees growing demand for its cardiac monitoring services. \n</p>\n<p>\n  The stock rose 14% to $210 on Thursday in after-hours trading. Shares have more than doubled this year through market close. \n</p>\n<p>\n  The digital health care company now forecasts revenue of $735 million to $740 million for the year, up from its prior view of $720 million to $730 million. \n</p>\n<p>\n  The updated guidance comes after the company narrowed its loss to $5.2 million, or 16 cents a share, from $46.2 million, or $1.48 a share, a year earlier. \n</p>\n<p>\n  On an adjusted basis, loss per share was 6 cents. Analysts polled by FactSet expected an adjusted loss of 28 cents. \n</p>\n<p>\n  Revenue rose 31% to $192.9 million. Analysts expected $184.8 million. \n</p>\n<p>\n  The growth was driven in part by higher demand for cardiac monitoring services within core existing accounts, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 18:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRTC","symbol_name":"Irhythm Technologies Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579019441","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579019441","pubTimestamp":1761864480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of iRhythm Technologies climbed after the company raised its full-year guidance as it sees growing demand for its cardiac monitoring services.The stock rose 14% to $210 on Thursday in after-hours trading. Shares have more than doubled this year through market close.The digital health care company now forecasts revenue of $735 million to $740 million for the year, up from its prior view of $720 million to $730 million.The updated guidance comes after the company narrowed its loss to $5.2 million, or 16 cents a share, from $46.2 million, or $1.48 a share, a year earlier.On an adjusted basis, loss per share was 6 cents. Analysts polled by FactSet expected an adjusted loss of 28 cents.Revenue rose 31% to $192.9 million. Analysts expected $184.8 million.The growth was driven in part by higher demand for cardiac monitoring services within core existing accounts, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRTC":"Irhythm Technologies Inc.","BK4563":"昨日强势股","BK4082":"医疗保健设备"},"translate_title":"iRhythm Technologies股价因上调财年指引而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRTC":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of iRhythm Technologies climbed after the company raised its full-year guidance as it sees growing demand for its cardiac monitoring services. \n\n\n  The stock rose 14% to $210 on Thursday in after-hours trading. Shares have more than doubled this year through market close. \n\n\n  The digital health care company now forecasts revenue of $735 million to $740 million for the year, up from its prior view of $720 million to $730 million. \n\n\n  The updated guidance comes after the company narrowed its loss to $5.2 million, or 16 cents a share, from $46.2 million, or $1.48 a share, a year earlier. \n\n\n  On an adjusted basis, loss per share was 6 cents. Analysts polled by FactSet expected an adjusted loss of 28 cents. \n\n\n  Revenue rose 31% to $192.9 million. Analysts expected $184.8 million. \n\n\n  The growth was driven in part by higher demand for cardiac monitoring services within core existing accounts, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 18:48 ET (22:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}